| From: richardred | 8/17/2010 12:01:51 AM | | | | | | | Order execution today-OLIN-OLN -I've been out of it for quite awhile. I do think the possibilities for a take out have risen quite a bit. The metals division was sold and the small caliber ammunition division should be sold. CA can be a cash cow when pricing and volume remain favorable. Still have a ways to go for that to happen. Meanwhile the dividend will keep me interested in holding. |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: richardred | 8/17/2010 1:01:40 PM | | | | | | Potash Corp. soars as BHP Billiton's $38.6 billion bid rejected
Stock hits highest in two years; shareholder rights plan adopted
Explore related topics
UK Potash Corporation of Saskatchewan Inc. Mosaic Co Agrium Inc.
Story Quotes Comments Screener (37)
Alert Email Print Share
By Aude Lagorce and Christopher Hinton, MarketWatch
NEW YORK (MarketWatch) -- Potash Corp. of Saskatchewan Inc. shares hit a two-year high after the fertilizer company said Tuesday it rejected a $38.6 billion takeover bid from BHP Billiton and rebuffed suggestions it enter into formal negotiations with the mining giant.
marketwatch.com |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| To: richardred who wrote (2300) | 8/17/2010 1:03:07 PM | | From: richardred | | | | Pactiv to be acquired by Reynolds for $6 billion
Related stories
NEW YORK (MarketWatch) -- Pactiv Corp. /quotes/comstock/13*!ptv/quotes/nls/ptv (PTV 32.55, +1.63, +5.29%) said Tuesday it would be acquired by Reynolds Group Holdings Ltd. for $33.25 a share in a deal valued at about $6 billion. The offer represents a 39% premium to Pactiv's May 14 closing price, the last trading day before reports of a potential transaction. The deal is expected to close before the end of 2010. Reynolds has reportedly obtained committed financing for the transaction, consisting of a combination of equity from Reynolds and Rank Group Limited, and committed debt financing provided by affiliates of Credit Suisse, HSBC, and Australia New Zealand Bank. Shares of Pactiv rose 5.4% at last check to $32.59.
marketwatch.com |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: richardred who wrote (2315) | 8/17/2010 1:05:35 PM | | From: richardred | | | | UPDATE 1-Medtronic to buy Osteotech for about $120 mln
Aug 17 (Reuters) - Medtronic Inc (MDT.N) agreed to buy orthopedic products maker Osteotech (OSTE.O) for about $120 million to add regenerative medicine to its biologics portfolio.
The $6.50 per share cash offer from the medical device maker, represents a premium of 65 percent over Osteotech's Monday close of $3.94 on Nasdaq.
Medtronic's offer comes amidst a tussle between Osteotech and a group of its shareholders that had most recently nominated four people to the company's board.
Osteotech, which had been evaluating strategic alternatives, said its current board had unanimously approved the deal.
Shares of the Eatontown, New Jersey-based Osteotech, which focuses on regenerative medicine, were up 64 percent at $6.49 Tuesday morning. (Reporting by Vidya L Nathan in Bangalore; Editing by Aradhana Aravindan)
reuters.com |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: richardred who wrote (2261) | 8/17/2010 11:47:49 PM | | From: richardred | | | | I missed the boat on this one.
Dell to Buy 3PAR for $1.15 Billion
Dell Inc. plans to purchase data-storage company 3PAR Inc. for about $1.15 billion in cash, as the personal-computer maker, playing catch-up with bigger rivals, seeks to boost its offerings for corporate-technology departments.
Dell said Monday it will pay $18 a share for 3PAR, an 87% premium to 3PAR's Friday closing price of $9.65. The boards of both companies have approved the 3PAR deal, which Dell said will add to a certain measure of its earnings in its 2012 fiscal year. 3PAR, which went public in 2007, has about 650 employees and earned $194 million in revenue for its 2010 ..
Read more: online.wsj.com |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: richardred | 8/19/2010 8:43:29 AM | | | | | | Intel buying McAfee for $7.7 billion
NEW YORK (MarketWatch) -- Intel Corp. /quotes/comstock/15*!intc/quotes/nls/intc (INTC 19.21, -0.38, -1.94%) said Thursday it'll pay $48 a share in cash to buy security software specialist McAfee Inc. /quotes/comstock/13*!mfe/quotes/nls/mfe (MFE 47.30, +17.37, +58.04%) in a deal valued at $7.7 billion. The price represents a premium of 62% over McAfee's closing price of $29.93 a share on Wednesday. Shares of McAfee jumped 58% to $47.40 in pre-market trades.
marketwatch.com |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: richardred | 8/19/2010 11:38:56 AM | | | | | | New buy on weakness today-MELA very risky-MELA Sciences-Insiders have been buying.
Company is awaiting FDA approval for their screening device.
About MELA Sciences
MELA Sciences is a medical technology company focused on developing MelaFind®, a non-invasive and objective computer vision system intended to aid in the detection of early melanoma. MELA Sciences designed MelaFind to assist in the evaluation of pigmented skin lesions, including atypical moles, which have one or more clinical or historical characteristics of melanoma, before a final decision to biopsy has been rendered. MelaFind acquires and displays multi-spectral (from blue to near infrared) digital images of pigmented skin lesions and uses automatic image analysis and statistical pattern recognition to help identify lesions to be considered for biopsy to rule out melanoma.
The MelaFind Pre-Market Approval (PMA) application was filed with the U.S. Food and Drug Administration (FDA) in June 2009 and is currently under review at the FDA. MELA Sciences cannot predict either the timing of the FDA's decision on the PMA application or the outcome. FDA approval is required prior to marketing MelaFind in the United States. |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| |
